Cystic fibrosis and survival to 40 years: A case-control study

European Respiratory Journal

Volumn 36, Issue 6, 2010, Pages 1277-1283

  Simmonds, N J ^a   MacNeill, S J ^a   Cullinan, P ^a   Hodson, M E ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Adults; Ageing; Cystic fibrosis; Survival

Indexed keywords

ANTIBIOTIC AGENT; PANCREAS ENZYME;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; FAILURE TO THRIVE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE MUTATION; GENOTYPE; HAEMOPHILUS INFLUENZAE; HEMOPTYSIS; HETEROZYGOSITY; HOMOZYGOSITY; HOSPITAL ADMISSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; MECONIUM ILEUS; ONSET AGE; PNEUMOTHORAX; PRIORITY JOURNAL; PROBABILITY; PSEUDOMONAS INFECTION; RESPIRATORY DISTRESS; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; SURVIVAL;

ADULT; ANTI-BACTERIAL AGENTS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PNEUMOTHORAX; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SURVIVORS; VITAL CAPACITY;

EID: 78649759755     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00001710     Document Type: Article

References (30)

1. Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007; 29: 522-526.
2. Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ 1998; 316: 1771-1775.
3. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996; 143: 1007-1017.
4. Jaffe A, Bush A. Cystic fibrosis: review of the decade. Monaldi Arch Chest Dis 2001; 56: 240-247.
5. De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61: 627-635.
6. Simmonds NJ, Cullinan P, Hodson ME. Growing old with cystic fibrosis: the characteristics of long-term survivors of cystic fibrosis. Respir Med 2008; 103: 629-635.
7. Hodson ME, Simmonds NJ, Warwick WJ, et al. An international/ multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J Cyst Fibros 2008; 7: 537-542.
8. Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005; 353: 1443-1453.
9. Schechter MS. Non-genetic influences on cystic fibrosis lung disease: the role of sociodemographic characteristics, environmental exposures, and healthcare interventions. Semin Respir Crit Care Med 2003; 24: 639-652.
10. Nick JA, Rodman DM. Manifestations of cystic fibrosis diagnosed in adulthood. Curr Opin Pulm Med 2005; 11: 513-518.
11. Rodman DM, Polis JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005; 171: 621-626.
12. Schechter MS, Margolis PA. Relationship between socioeconomic status and disease severity in cystic fibrosis. J Pediatr 1998; 132: 260-264.
13. Schechter MS, Shelton BJ, Margolis PA, et al. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001; 163: 1331-1337.
14. Britton JR. Effects of social class, sex, and region of residence on age at death from cystic fibrosis. BMJ 1989; 298: 483-487.
15. Kraemer R, Rudeberg A, Hadorn B, et al. Relative underweight in cystic fibrosis and its prognostic value. Acta Paediatr Scand 1978; 67: 33-37.
16. Corey M, McLaughlin FJ, Williams M, et al. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988; 41: 583-591.
17. Huang NN, Schidlow DV, Szatrowski TH, et al. Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis. Am J Med 1987; 82: 871-879.
18. Courtney JM, Bradley J, Mccaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007; 42: 525-532.
19. Lai HJ, Cheng Y, Cho H, et al. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol 2004; 159: 537-546.
20. Rosenfeld M, Davis R, FitzSimmons S, et al. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997; 145: 794-803.
21. Verma N, Bush A, Buchdahl R. Is there still a gender gap in cystic fibrosis? Chest 2005; 128: 2824-2834.
22. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
23. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12: 158-161.
24. Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest 2005; 128: 729-738.
25. Watkin SL, Elborn JS, Cordon SM, et al. C-reactive protein is not a useful indicator of intermittent bacterial colonization in early lung disease of patients with cystic fibrosis. Pediatr Pulmonol 1994; 17: 6-10.
26. Navarro J, Rainisio M, Harms HK, et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2001; 18: 298-305.
27. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003; CD001912.
28. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-1080. (Pubitemid 19231815)
29. UK Cystic Fibrosis Database. Annual Data Report 2004. University of Dundee 2006. www.cystic-fibrosis.org.uk/pdfs/annualreport/AuditReport2004.pdf Date last accessed: October 4, 2010. Date last updated: April, 2: 2010.
30. Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984; 104: 206-210.